Cyclopentolate Online

How and where to order Cyclopentolate Hydrochloride (Cyclogyl) 1% 5 ml ophthalmic solution online on the American Board of Clinical Optometry website:

Shop:	MEDS FOR SALE
Prices:	from $6.83 per bottle
Discount:	5% coupon: 5OFF
Forms:	1% 5 ml eye drops
Quantity:	1-6 bottles
Type:	Cyclopent brand, Cyclogyl generic
Payment:	Visa, Mastercard, AmEx, Cryptocurrencies
Delivery:	Regular airmail and express courier
Shipping:	Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Cyclogyl (Cyclopentolate Hydrochloride) ophthalmic solution is used to produce mydriasis and cycloplegia.

Dosage and administration:

Adults

Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days.

Children

Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary.

Small infants

A single instillation of one drop of 0.5% in theeye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation. Individuals with heavily pigmented irides may require higher strengths.

Dosage forms and strengths:

Cyclogyl (Cyclopentolate Hydrochloride) eye drops 0.5%, 1%, 2% in multiple-dose plastic dispensers 2 ml, 5 ml, 15 ml.

Contraindications:

Ophthalmic Cyclopentolate HCl should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this medication.

Warnings:

Cyclogyl (Cyclopentolate HCl) eye drops is for topical ophthalmic use only, not for injection. This medication may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% Cyclogyl solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.

Mydriatics may produce a transient elevation of intraocular pressure.

Overdosage:

Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.

Precautions:

The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma.

Side effects, adverse reactions:

Ocular

Most common adverse reactions of Cyclogyl eye drops are increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae.

Non-ocular

Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.

Drug interactions:

Cyclopentolate (Cyclogyl) may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.

Use in specific populations:

Pregnancy

Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclogyl should be administered to a pregnant woman only if clearly needed.

Nursing mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.

Pediatric use

Use of Cyclogyl has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four hours after examination. Observe infants closely for at least 30 minutes.

Geriatric use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Information for patients:

Do not touch dropper tip to any surface, as this may contaminate the solution.

A transient burning sensation may occur upon instillation.

Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated.

Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.

Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration.

Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four hours after examination.

Here is a list of popular medications containing cyclopentolate hydrochloride as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

Trade name of the drug	Pharmaceutical forms and doses	Companies
Colircusi Cicloplejico	Drops; Ophthalmic; 1%	Alcon Summit
Cyclogyl	Solution; Ophthalmic; 0.5%, 1%, 2%	Alcon Andre Laboratories Intas Pharmaceuticals Novartis
Cyclopent	Drops; Ophthalmic; 1%	Sun Pharmaceutical Industries
Minims Cyclopentolate	Solution; Ophthalmic; 0.5%, 1%	Chauvin Pharmaceuticals Apex Pharma Bausch and Lomb Valeant Pharmaceuticals